Lake Street Downgrades Silk Road Medical to Hold, Lowers Price Target to $27.5
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Frank Takkinen has downgraded Silk Road Medical (NASDAQ:SILK) from Buy to Hold and lowered the price target from $28 to $27.5.
June 18, 2024 | 9:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Lake Street analyst Frank Takkinen downgraded Silk Road Medical from Buy to Hold and reduced the price target from $28 to $27.5.
The downgrade from Buy to Hold and the reduction in the price target from $28 to $27.5 by Lake Street analyst Frank Takkinen is likely to negatively impact investor sentiment and the short-term stock price of Silk Road Medical.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100